Keymed Biosciences expects H1 profit at least RMB 1.2 billion

• Keymed guided for H1 2026 profit of at least RMB 1.2 billion, versus a loss of about RMB 79 million a year earlier.
• Turnaround driven by other income of about RMB 1.68 billion from a Q2 upfront payment equivalent to USD 257 million tied to an Ouro Medicines stake disposal.
• Collaboration income of about RMB 220 million booked from a CMG901 milestone; cash received equivalent to USD 31.5 million from USD 45 million triggered.
• Kangyueda product revenue topped RMB 390 million in H1, up more than 132% year on year; pricing set at RMB 1,039 per 300 mg/2 mL unit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260715-12245879), on July 15, 2026, and is solely responsible for the information contained therein.